NUP62CL as an Immunological and Prognostic Biomarker of Oral Squamous Cell Carcinoma

References

• Mao L, Zhuang R, Qin L, et al. CCL18 overexpression predicts a worse prognosis in oral squamous cell carcinoma (OSCC). Neoplasma. 2020;67(3):700–706. doi:10.4149/neo_2020_190821N802
   PubMed Web of Science ®Google Scholar
• Peres MA, Macpherson LMD, Weyant RJ, et al. Oral diseases: a global public health challenge. Lancet. 2019;394(10194):249–260. doi:10.1016/S0140-6736(19)31146-8
   PubMed Web of Science ®Google Scholar
• McCord C, Kiss A, Magalhaes MA, Leong IT, Jorden T, Bradley G. Oral squamous cell carcinoma associated with precursor lesions. Cancer Prev Res. 2021;14(9):873–884. doi:10.1158/1940-6207.CAPR-21-0047
   PubMedGoogle Scholar
• Jiang M, Li B. STAT3 and its targeting inhibitors in oral squamous cell carcinoma. Cells. 2022;11(19):3131. doi:10.3390/cells11193131
   PubMed Web of Science ®Google Scholar
• Chen Y, Feng Y, Yan F, Zhao Y, Zhao H, Guo Y. A novel immune-related gene signature to identify the tumor microenvironment and prognose disease among patients with oral squamous cell carcinoma patients using ssGSEA: a bioinformatics and biological validation study. Front Immunol. 2022;13:922195. doi:10.3389/fimmu.2022.922195
   PubMed Web of Science ®Google Scholar
• Zhao X, Sun S, Zeng X, Cui L. Expression profiles analysis identifies a novel three-mRNA signature to predict overall survival in oral squamous cell carcinoma. Am J Cancer Res. 2018;8(3):450–461.
   PubMedGoogle Scholar
• Wang PC, Hu ZQ, Zhou SL, et al. The spatial distribution of immune cell subpopulations in hepatocellular carcinoma. Cancer Sci. 2022;113(2):423–431. doi:10.1111/cas.15202
   PubMedGoogle Scholar
• Tang N, Ning Q, Wang Z, Tao Y, Zhao X, Tang S. Tumor microenvironment based stimuli-responsive CRISPR/Cas delivery systems: a viable platform for interventional approaches. Colloids Surf B Biointerfaces. 2022;210:112257. doi:10.1016/j.colsurfb.2021.112257
   PubMedGoogle Scholar
• Liu T, Tan J, Wu M, et al. High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39(+)CD8(+) T cells. Gut. 2021;70(10):1965–1977. doi:10.1136/gutjnl-2020-322196
   PubMed Web of Science ®Google Scholar
• Schneider K, Marbaix E, Bouzin C, et al. Immune cell infiltration in head and neck squamous cell carcinoma and patient outcome: a retrospective study. Acta Oncol. 2018;57(9):1165–1172. doi:10.1080/0284186X.2018.1445287
   PubMed Web of Science ®Google Scholar
• Yi C, Chen L, Lin Z, et al. Lenvatinib targets FGF receptor 4 to enhance antitumor immune response of anti-programmed cell death-1 in HCC. Hepatology. 2021;74(5):2544–2560. doi:10.1002/hep.31921
   PubMed Web of Science ®Google Scholar
• Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016;17(7):956–965. doi:10.1016/S1470-2045(16)30066-3
   PubMed Web of Science ®Google Scholar
• Ren S, Wang W, Zhang C, et al. The low expression of NUP62CL indicates good prognosis and high level of immune infiltration in lung adenocarcinoma. Cancer Med. 2021;10(10):3403–3412. doi:10.1002/cam4.3877
   PubMedGoogle Scholar
• Singh U, Bindra D, Samaiya A, Mishra RK. Overexpressed Nup88 stabilized through interaction with Nup62 promotes NF-kappaB dependent pathways in cancer. Front Oncol. 2023;13:1095046. doi:10.3389/fonc.2023.1095046
   PubMedGoogle Scholar
• Mullan PB, Bingham V, Haddock P, et al. NUP98 - a novel predictor of response to anthracycline-based chemotherapy in triple negative breast cancer. BMC Cancer. 2019;19(1):236. doi:10.1186/s12885-019-5407-9
   PubMedGoogle Scholar
• Wu Y, Fang G, Wang X, et al. NUP153 overexpression suppresses the proliferation of colorectal cancer by negatively regulating Wnt/beta-catenin signaling pathway and predicts good prognosis. Cancer Biomark. 2019;24(1):61–70. doi:10.3233/CBM-181703
   PubMedGoogle Scholar
• Hazawa M, Lin DC, Kobayashi A, et al. ROCK-dependent phosphorylation of NUP62 regulates p63 nuclear transport and squamous cell carcinoma proliferation. EMBO Rep. 2018;19(1):73–88. doi:10.15252/embr.201744523
   PubMed Web of Science ®Google Scholar
• Chen F, Chandrashekar DS, Varambally S, Creighton CJ. Pan-cancer molecular subtypes revealed by mass-spectrometry-based proteomic characterization of more than 500 human cancers. Nat Commun. 2019;10(1):5679. doi:10.1038/s41467-019-13528-0
   PubMed Web of Science ®Google Scholar
• Agle K, Vincent BG, Piper C, et al. Bim regulates the survival and suppressive capability of CD8(+) FOXP3(+) regulatory T cells during murine GVHD. Blood. 2018;132(4):435–447. doi:10.1182/blood-2017-09-807156
   PubMedGoogle Scholar
• Togni L, Caponio VCA, Zerman N, et al. The emerging impact of tumor budding in oral squamous cell carcinoma: main issues and clinical relevance of a new prognostic marker. Cancers. 2022;14(15):3571. doi:10.3390/cancers14153571
   PubMedGoogle Scholar
• Sangro B, Sarobe P, Hervas-Stubbs S, Melero I. Advances in immunotherapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021;18(8):525–543. doi:10.1038/s41575-021-00438-0
   PubMed Web of Science ®Google Scholar
• Arneth B. Tumor Microenvironment. Medicina. 2019;56(1):15. doi:10.3390/medicina56010015
   PubMed Web of Science ®Google Scholar
• Borsetto D, Tomasoni M, Payne K, et al. Prognostic significance of CD4+ and CD8+ tumor-infiltrating lymphocytes in head and neck squamous cell carcinoma: a meta-analysis. Cancers. 2021;13(4):781. doi:10.3390/cancers13040781
   PubMed Web of Science ®Google Scholar
• Troiano G, Caponio VCA, Adipietro I, et al. Prognostic significance of CD68(+) and CD163(+) tumor associated macrophages in head and neck squamous cell carcinoma: a systematic review and meta-analysis. Oral Oncol. 2019;93:66–75. doi:10.1016/j.oraloncology.2019.04.019
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang Y, Ren Y, Zhang Q, Yi P, Cheng C. Metabolic modulation of immune checkpoints and novel therapeutic strategies in cancer. Semin Cancer Biol. 2022;86(Pt 3):542–565. doi:10.1016/j.semcancer.2022.02.010
   PubMedGoogle Scholar
• Damasio MPS, Nascimento CS, Andrade LM, de Oliveira VL, Calzavara-Silva CE. The role of T-cells in head and neck squamous cell carcinoma: from immunity to immunotherapy. Front Oncol. 2022;12:1021609. doi:10.3389/fonc.2022.1021609
   PubMedGoogle Scholar
• Kao HF, Lou PJ. Immune checkpoint inhibitors for head and neck squamous cell carcinoma: current landscape and future directions. Head Neck. 2019;41(Suppl 1):4–18. doi:10.1002/hed.25930
   PubMedGoogle Scholar
• Yu GT, Bu LL, Zhao YY, et al. CTLA4 blockade reduces immature myeloid cells in head and neck squamous cell carcinoma. Oncoimmunology. 2016;5(6):e1151594. doi:10.1080/2162402X.2016.1151594
   PubMedGoogle Scholar
• Qi X, Jia B, Zhao X, Yu D. Advances in T-cell checkpoint immunotherapy for head and neck squamous cell carcinoma. Onco Targets Ther. 2017;10:5745–5754. doi:10.2147/OTT.S148182
   PubMed Web of Science ®Google Scholar
• Sarkizova S, Hacohen N. How T cells spot tumour cells. Nature. 2017;551(7681):444–446. doi:10.1038/d41586-017-07267-9
   PubMedGoogle Scholar
• Luksza M, Riaz N, Makarov V, et al. A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy. Nature. 2017;551(7681):517–520.
   PubMed Web of Science ®Google Scholar